Genetic polymorphisms of CYP3A5, CHRM2, and ZNF498 and their association with epilepsy susceptibility: a pharmacogenetic and case–control study

BACKGROUND: A total of 50 million persons were diagnosed worldwide with epilepsy. One-third of them are experiencing debilitating seizures despite optimum anti‐epileptic drugs (AEDs) treatment. Several studies have suggested that CYP3A5, CHRM2, and ZNF498 influence the pharmacokinetics of AEDs. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: AL-Eitan, Laith N, Al-Dalalah, Islam M, Mustafa, Mohamed M, Alghamdi, Mansour A, Elshammari, Afrah K, Khreisat, Wael H, Al-Quasmi, Mohammed N, Aljamal, Hanan A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732506/
https://www.ncbi.nlm.nih.gov/pubmed/31564953
http://dx.doi.org/10.2147/PGPM.S212433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6732506/
https://www.ncbi.nlm.nih.gov/pubmed/31564953
http://dx.doi.org/10.2147/PGPM.S212433

Ejemplares similares